{"id":6011,"date":"2022-09-06T11:16:24","date_gmt":"2022-09-06T08:16:24","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=6011"},"modified":"2022-09-06T11:17:35","modified_gmt":"2022-09-06T08:17:35","slug":"klimik-eriskin-bagisiklamasi-calisma-grubu-ebcgndan-covid-19-varyant-asilari-hakkinda-bilgi-notu","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/klimik-eriskin-bagisiklamasi-calisma-grubu-ebcgndan-covid-19-varyant-asilari-hakkinda-bilgi-notu\/","title":{"rendered":"KL\u0130M\u0130K Eri\u015fkin Ba\u011f\u0131\u015f\u0131klamas\u0131 \u00c7al\u0131\u015fma Grubu&#8217;ndan COVID-19 Varyant A\u015f\u0131lar\u0131 Hakk\u0131nda Bilgi Notu"},"content":{"rendered":"<p>COVID-19 pandemisinde s\u00fcreci en \u00e7ok etkileyen fakt\u00f6rlerden olan a\u015f\u0131 uygulamalar\u0131nda ge\u00e7en hafta yeni bir geli\u015fme ya\u015fand\u0131. Amerikan G\u0131da ve \u0130la\u00e7 Dairesi (FDA), 31 A\u011fustos 2022 tarihinde yapt\u0131\u011f\u0131 a\u00e7\u0131klama ile \u2018Varyant A\u015f\u0131\u2019 olarak tan\u0131mlanan bivalan mRNA a\u015f\u0131lar\u0131na onay verdi\u011fini a\u00e7\u0131klad\u0131. Aral\u0131k 2021\u2019de FDA acil kullan\u0131m onaylar\u0131n\u0131 alan mRNA a\u015f\u0131lar\u0131 [Pfizer-BioNTech (BNT162b2) ve Moderna (mRNA-1273)] halen t\u00fcm d\u00fcnyada kullan\u0131lan a\u015f\u0131lar i\u00e7erisinde hastal\u0131\u011f\u0131 engelleme ve a\u011f\u0131r infeksiyonu \u00f6nleme konusunda en etkili a\u015f\u0131lar olmakla birlikte yeni varyantlara kar\u015f\u0131 koruyuculu\u011fun azald\u0131\u011f\u0131 g\u00f6zlenmekteydi. Gerek deneysel \u00e7al\u0131\u015fmalar gerekse ger\u00e7ek ya\u015fam verileri a\u015f\u0131 etkilili\u011finin azald\u0131\u011f\u0131n\u0131 g\u00f6sterdi\u011finden bu varyantlara kar\u015f\u0131 etkili a\u015f\u0131 \u015femalar\u0131 ve yeni a\u015f\u0131 geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131 h\u0131z kazanm\u0131\u015ft\u0131. Bu \u00e7al\u0131\u015fmalar sonucunda orijinal (Wuhan) virusu ile birlikte Omikron BA4\/BA5 varyantlar\u0131na kar\u015f\u0131 antikor sa\u011flayan ikili (bivalan) a\u015f\u0131lar geli\u015ftirilmi\u015f ve FDA taraf\u0131ndan hem \u00f6nceki \u00e7al\u0131\u015fmalar\u0131n verileri ele al\u0131narak hem de klinik ara\u015ft\u0131rma \u015feklinde olmayan ara\u015ft\u0131rmalar\u0131n detayl\u0131 analizleri yap\u0131larak 31 A\u011fustos 2022\u2019de acil kullan\u0131m onay\u0131 alm\u0131\u015ft\u0131r. FDA acil kullan\u0131m onay\u0131 verirken, \u00f6zellikle okullar\u0131n da a\u00e7\u0131lmas\u0131 ile birlikte Eyl\u00fcl ve Ekim aylar\u0131 i\u00e7inde vaka say\u0131s\u0131n\u0131n artaca\u011f\u0131 \u00f6ng\u00f6r\u00fcs\u00fcn\u00fcn etkili oldu\u011funu vurgulam\u0131\u015ft\u0131r.<\/p>\n<p>Omikron varyantlar\u0131na kar\u015f\u0131 daha y\u00fcksek bir etkinlik sunmas\u0131 beklenen bivalan a\u015f\u0131lar\u0131n mRNA a\u015f\u0131s\u0131 ile a\u015f\u0131lanm\u0131\u015f ve primer a\u015f\u0131 \u015femas\u0131n\u0131 tamamlam\u0131\u015f ve son a\u015f\u0131n\u0131n \u00fczerinden en az iki ay ge\u00e7en veya herhangi bir g\u00fcncel COVID-19 a\u015f\u0131s\u0131 uygulamas\u0131 \u00fczerinden iki ay ge\u00e7en eri\u015fkinler (&gt;18 ya\u015f) i\u00e7in uygun oldu\u011fu belirtilmektedir. FDA \u00e7ocuk ya\u015f grubu i\u00e7in12-18 ya\u015f aral\u0131\u011f\u0131nda Pfizer Biontech bivalan a\u015f\u0131s\u0131n\u0131 \u00f6nerirken Moderna bivalan a\u015f\u0131s\u0131 i\u00e7in ise daha fazla bilgiye ihtiya\u00e7 duyuldu\u011funa dikkat \u00e7ekmektedir.<\/p>\n<p>G\u00fcncel bilgiler \u0131\u015f\u0131\u011f\u0131nda;<\/p>\n<ul>\n<li>Bivalan a\u015f\u0131lar en az iki doz mRNA a\u015f\u0131s\u0131yla a\u015f\u0131lanm\u0131\u015f ki\u015filere rapel (hat\u0131rlatma) a\u015f\u0131 dozu olarak \u00f6nerilmektedir.<\/li>\n<li>Bundan sonra hat\u0131rlatma dozlar\u0131n\u0131n bivalan a\u015f\u0131larla yap\u0131lmas\u0131 \u00f6nerilmekle birlikte COVID-19 a\u015f\u0131lar\u0131n\u0131 <em><u>hala tamamlamam\u0131\u015f olan<\/u><\/em> sa\u011fl\u0131kl\u0131 veya riskli gruplardan 12 ya\u015f \u00fcst\u00fc t\u00fcm vatanda\u015flar\u0131m\u0131z\u0131n yeni a\u015f\u0131lar \u00fclkemize gelene kadar mevcut mRNA a\u015f\u0131lar\u0131 ile a\u015f\u0131 \u015femalar\u0131n\u0131 tamamlamalar\u0131 \u00f6nerilir.<\/li>\n<li>Hen\u00fcz \u00fclkemizde bulunmayan bivalan a\u015f\u0131lar\u0131n en k\u0131sa s\u00fcrede \u00fclkemizde de kullan\u0131ma girmesi \u00f6zellikle riskli gruplar i\u00e7in gereklidir.<\/li>\n<li>Bivalan a\u015f\u0131lar\u0131n yan etki profili a\u00e7\u0131s\u0131ndan mevcut RNA a\u015f\u0131lar\u0131ndan bir farkl\u0131l\u0131k olu\u015fturmas\u0131 beklenmemektedir.<\/li>\n<\/ul>\n<p>Derne\u011fimizin g\u00fcncel COVID-19 a\u015f\u0131 \u00f6nerilerine <a href=\"https:\/\/www.klimik.org.tr\/?p=119309\" target=\"_blank\" rel=\"noopener noreferrer\"><strong>buradan<\/strong><\/a> ula\u015fabilirsiniz.<\/p>\n<p>Sayg\u0131lar\u0131m\u0131zla<\/p>\n<p><strong>Klimik EB\u00c7G Y\u00fcr\u00fctme Kurulu<\/strong><\/p>\n<p><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use\"><strong>FDA Duyurusu \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>COVID-19 pandemisinde s\u00fcreci en \u00e7ok etkileyen fakt\u00f6rlerden olan a\u015f\u0131 uygulamalar\u0131nda ge\u00e7en hafta yeni bir geli\u015fme ya\u015fand\u0131. Amerikan G\u0131da ve \u0130la\u00e7 Dairesi (FDA), 31 A\u011fustos 2022 tarihinde yapt\u0131\u011f\u0131 a\u00e7\u0131klama ile \u2018Varyant A\u015f\u0131\u2019 olarak tan\u0131mlanan bivalan mRNA a\u015f\u0131lar\u0131na onay verdi\u011fini a\u00e7\u0131klad\u0131. Aral\u0131k 2021\u2019de FDA acil kullan\u0131m onaylar\u0131n\u0131 alan mRNA a\u015f\u0131lar\u0131 [Pfizer-BioNTech (BNT162b2) ve Moderna (mRNA-1273)] halen t\u00fcm d\u00fcnyada kullan\u0131lan a\u015f\u0131lar i\u00e7erisinde hastal\u0131\u011f\u0131 engelleme ve a\u011f\u0131r infeksiyonu \u00f6nleme konusunda en etkili a\u015f\u0131lar olmakla birlikte yeni varyantlara kar\u015f\u0131 koruyuculu\u011fun azald\u0131\u011f\u0131 g\u00f6zlenmekteydi. Gerek deneysel \u00e7al\u0131\u015fmalar gerekse ger\u00e7ek ya\u015fam verileri a\u015f\u0131 etkilili\u011finin azald\u0131\u011f\u0131n\u0131 g\u00f6sterdi\u011finden bu varyantlara kar\u015f\u0131 etkili a\u015f\u0131 \u015femalar\u0131 ve yeni a\u015f\u0131 geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131 h\u0131z [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":5997,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/6011"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=6011"}],"version-history":[{"count":2,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/6011\/revisions"}],"predecessor-version":[{"id":6013,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/6011\/revisions\/6013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5997"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=6011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=6011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=6011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}